You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company will receive no proceeds from the offering but could receive $34.8 million if warrants included in the offering are exercised in full.
Some of the proceeds will be used to fund development of the firm's NexGen molecular diagnostics system.
The offering is expected to bring in net proceeds of at least $877.4 million.
Net proceeds will be used to pay a part of its acquisition of Beckman Coulter, which is expected to close by the end of the month.
The firm expects to use proceeds to fund R&D efforts, including development of its next-generation molecular diagnostics system.
The company raised about $73.8 million in net proceeds, which will go toward expansion of its facilities and further development of its sequencing technology.
The company anticipates netting $64.1 million in proceeds from the offering.
The firm sold 15,686,000 shares of common stock at a price of $2.20 per share.
The firm is selling nearly 1.2 million shares at $1.99 per share in a direct offering.
Opko said it may use some of the proceeds to make additional acquisitions.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.
Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.
According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.
In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.